CD274 and non-small cell lung carcinoma: In advanced NSCLC, high levels of soluble PD-L1/CD274 correlated with nivolumab treatment failure [39], and serum with a high proportion of PD-L1/CD274+ exosomes, have been shown to inhibit in vitro IL-2 and IFN-γ production by CD8+ T cells [40].